Streetbeat News

Products Services

VRAX

Virax Biolabs Group Limited (VRAX) CEO James Foster issued a shareholder letter detailing the company's progress in immunology research, particularly in post viral syndromes and chronic inflammation. The company has developed a SARS-Cov-2 version of its ViraxImmune T-Cell Kit and is collaborating with a UK research institute. Virax is also enhancing its IVD platform with FluoroSpot technology for better immune response analysis. Financially, Virax is in a strong position with $5.6 million in cash and no debt after a warrant exercise in October 2023. The stock is currently trading at 57% of cash value. The company anticipates significant advancements in its FluoroSpot assays and expansion of distribution channels in the next 12 months.

Portfolio Pulse from Benzinga Newsdesk

December 18, 2023 | 12:44 pm

AADI

DRRX

KTRA

The article highlights three health care stocks that are considered oversold based on their Relative Strength Index (RSI) values, suggesting a potential buying opportunity for undervalued companies. Kintara Therapeutics, Inc. (KTRA) has an RSI of 21.46 and experienced a 46% stock price drop over the past month. Aadi Bioscience, Inc. (AADI) reported interim trial results and saw a 54% decline in stock price over five days, with an RSI of 23.73. DURECT Corporation (DRRX) posted disappointing sales and a 9% stock price decrease over the past month, with an RSI of 27.92.

Portfolio Pulse from Avi Kapoor

December 18, 2023 | 12:39 pm

WBX

Weavegrid and Wallbox have partnered to enhance utility-managed EV charging programs for Wallbox owners in North America, starting with Xcel Energy's Charging Perks Program in Colorado, which caters to approximately 1.3 million residential customers.

Portfolio Pulse from Benzinga Newsdesk

December 18, 2023 | 12:37 pm

GPCR

Structure Therapeutics Inc. (NASDAQ:GPCR) announced a comprehensive update on its GSBR-1290 program, including positive Phase 2a clinical study results for the oral GLP-1 receptor agonist aimed at treating metabolic and cardiopulmonary diseases.

Portfolio Pulse from Benzinga Newsdesk

December 18, 2023 | 12:35 pm

LLY

OGN

Organon (OGN) has entered into an agreement with Eli Lilly (LLY) to become the sole distributor and promoter of Lilly's migraine medications, Emgality (Galcanezumab) and Reyvow (Lasmiditan), in Europe. The deal includes an upfront payment of $50 million from Organon to Lilly, along with additional sales-based milestone payments.

Portfolio Pulse from Benzinga Newsdesk

December 18, 2023 | 12:34 pm

FCEL

XOM

ExxonMobil is collaborating with FuelCell Energy to construct a pilot plant utilizing carbonate fuel cell technology. This initiative is part of ExxonMobil's efforts to reduce carbon emissions and explore energy-efficient solutions.

Portfolio Pulse from Benzinga Newsdesk

December 18, 2023 | 12:32 pm

LNTH

PNT

Lantheus Holdings, Inc. (LNTH) and POINT Biopharma Global Inc. (PNT) announced positive topline results from the Phase 3 SPLASH study for 177Lu-PNT2002, a treatment for metastatic castration-resistant prostate cancer. The study met its endpoints, showing efficacy and safety after progression on an ARPI.

Portfolio Pulse from Benzinga Newsdesk

December 18, 2023 | 12:31 pm

ACHL

Achilles Therapeutics has announced the publication of a 'Comment' in Nature Cancer discussing strategies for better prediction of neoantigen immunogenicity, which is crucial for the development of cancer immunotherapies.

Portfolio Pulse from Benzinga Newsdesk

December 18, 2023 | 12:22 pm

BCDA

BioCardia, Inc. anticipates submitting for approval of its CardiAMP Heart Failure treatment in Japan by late Q4 2024, following a consultation with the Japan Pharmaceutical and Medical Device Agency (PMDA). The submission will be based on the existing data.

Portfolio Pulse from Benzinga Newsdesk

December 18, 2023 | 12:18 pm

HUBC

HUB Cyber Security has expanded its collaboration with a major entertainment company to integrate its cybersecurity services across the company's global branches. The deal aims to strengthen the digital infrastructure and improve defenses against cybersecurity threats. No financial terms of the deal were disclosed.

Portfolio Pulse from Benzinga Newsdesk

December 18, 2023 | 12:14 pm